These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21352258)

  • 41. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EGFR and cyclin D1 in nodular melanoma: correlation with pathohistological parameters and overall survival.
    Katunarić M; Jurišić D; Petković M; Grahovac M; Grahovac B; Zamolo G
    Melanoma Res; 2014 Dec; 24(6):584-91. PubMed ID: 25304234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
    Settleman J
    Cancer Cell; 2009 Oct; 16(4):278-9. PubMed ID: 19800573
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutated ERBB4: a novel drug target in metastatic melanoma?
    Kurppa K; Elenius K
    Pigment Cell Melanoma Res; 2009 Dec; 22(6):708-10. PubMed ID: 19735458
    [No Abstract]   [Full Text] [Related]  

  • 46. HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma.
    Nielsen TO; Poulsen SS; Journe F; Ghanem G; Sorensen BS
    Melanoma Res; 2014 Feb; 24(1):88-91. PubMed ID: 24366194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations in ERBB4 may have a minor role in melanoma pathogenesis.
    Manca A; Lissia A; Cossu A; Rubino C; Ascierto PA; Stanganelli I; Palmieri G
    J Invest Dermatol; 2013 Jun; 133(6):1685-7. PubMed ID: 23340734
    [No Abstract]   [Full Text] [Related]  

  • 48. Molecular biomarkers of prognosis in melanoma: how far are we from the clinic?
    Schramm SJ; Menzies AM; Mann GJ
    Melanoma Res; 2013 Dec; 23(6):423-5. PubMed ID: 24165033
    [No Abstract]   [Full Text] [Related]  

  • 49. Gene Expression Profiling in Cutaneous Melanoma: Caveats for Clinicians.
    Sominidi-Damodaran S; Pittelkow MR; Meves A
    Mayo Clin Proc; 2016 Aug; 91(8):1147-8. PubMed ID: 27492918
    [No Abstract]   [Full Text] [Related]  

  • 50. Molecular Profiling in Cutaneous Melanoma.
    Ji AL; Bichakjian CK; Swetter SM
    J Natl Compr Canc Netw; 2016 Apr; 14(4):475-80. PubMed ID: 27059194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Melanoma molecular classes and prognosis in the postgenomic era.
    Tremante E; Ginebri A; Lo Monaco E; Frascione P; Di Filippo F; Terrenato I; Benevolo M; Mottolese M; Pescarmona E; Visca P; Natali PG; Giacomini P
    Lancet Oncol; 2012 May; 13(5):e205-11. PubMed ID: 22554548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abnormal expression of MAPK, EGFR, CK17 and TGk in the skin lesions of chloracne patients exposed to dioxins.
    Liu J; Zhang CM; Coenraads PJ; Ji ZY; Chen X; Dong L; Ma XM; Han W; Tang NJ
    Toxicol Lett; 2011 Mar; 201(3):230-4. PubMed ID: 21237254
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing Genetic Expression Profiles in Melanoma Prognosis.
    Farberg AS; Glazer AM; Winkelmann RR; Rigel DS
    Dermatol Clin; 2017 Oct; 35(4):545-550. PubMed ID: 28886811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Future advances in melanoma research.
    Hornyak TJ
    Clin Plast Surg; 2010 Jan; 37(1):169-76. PubMed ID: 19914467
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of key genes involved in the pathogenesis of cutaneous melanoma using bioinformatics analysis.
    Chen J; Sun W; Mo N; Chen X; Yang L; Tu S; Zhang S; Liu J
    J Int Med Res; 2020 Jan; 48(1):300060519895867. PubMed ID: 31937175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of gene deletion in single metastatic tumor cells in the excision margin of a primary cutaneous melanoma.
    Pack SD; Boni R; Vortmeyer AO; Pak E; Zhuang Z
    J Natl Cancer Inst; 1998 May; 90(10):782-3. PubMed ID: 9605650
    [No Abstract]   [Full Text] [Related]  

  • 57. The mutation profiles of common oncogenes involved in melanoma in southern China.
    Zhou QM; Li W; Zhang X; Chen YB; Chen XC; Guan YX; Ding Y; Wen XZ; Xia Q; Zhou Q; Peng RQ; Hou JH; Zhu XF; Zeng YX; Zhang XS
    J Invest Dermatol; 2012 Jul; 132(7):1935-7. PubMed ID: 22437319
    [No Abstract]   [Full Text] [Related]  

  • 58. [Transcriptoma and melanoma: physiopathological and therapeutic implications].
    Dereure O
    Ann Dermatol Venereol; 2006; 133(6-7):581-4. PubMed ID: 16885850
    [No Abstract]   [Full Text] [Related]  

  • 59. Osteopontin in melanocytic lesions--a first step towards invasion?
    Sturm RA
    J Invest Dermatol; 2005 May; 124(5):xiv-xv. PubMed ID: 15854021
    [No Abstract]   [Full Text] [Related]  

  • 60. Consensus, Controversy, and Conversations About Gene Expression Profiling in Melanoma.
    Chan WH; Tsao H
    JAMA Dermatol; 2020 Sep; 156(9):949-951. PubMed ID: 32745178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.